Home / Generics / News / First generic version of Alzheimer’s patch launched in US

First generic version of Alzheimer’s patch launched in US Posted 25/09/2015

US generics company Alvogen announced on 31 August 2015 the launch of its generic equivalent of Novartis’s Alzheimer’s disease treatment Exelon patch (rivastigmine transdermal system) in the US.

Rivastigmine transdermal system is indicated for the treatment of mild, moderate and severe memory problems (dementia) associated with Alzheimer’s disease and for the treatment of mild and moderate dementia associated with Parkinson’s disease.

Alvogen’s product is the first generic version of the rivastigmine transdermal system in the US. It will be marketed by Alvogen in three strengths (4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs). Alvogen is the first filer for the 13.3 mg/24 hrs strength, giving the company 180 days of marketing exclusivity, for this strength.

Rival generics maker Actavis has also filed an abbreviated new drug application for the three strengths of the rivastigmine transdermal system [1].

Novartis’s Exelon patch, had sales of approximately US$400 million in the US during 2014, according to IMS data.

Related article
Alvotech invests US$250 million in biosimilars

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Actavis confirms generic Alzheimer’s patch patent challenge [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Sep 25]. Available from: www.gabionline.net/Generics/News/Actavis-confirms-generic-Alzheimer-s-patch-patent-challenge

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Source: Alvogen

Comments (0)

Generics News Research General

more

Biosimilars News Research General

more